Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA7 | P43166 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 6/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8024485 | 0.85 | TSHR (0.42) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL19972862 | 0.81 | — | — | |
| SCHEMBL826905 | 0.79 | TSHR (0.46) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL28890230 | 0.79 | TSHR (0.46) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL9678131 | 0.79 | TSHR (0.46) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL543811 | 0.78 | MAPT (0.35) | MAPT | |
| SCHEMBL4306399 | 0.77 | TSHR (0.43) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL12128600 | 0.77 | TSHR (0.43) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL454299 | 0.77 | TSHR (0.43) | TSHRMEN1KMT2APTPN1LMNA | |
| SCHEMBL5824309 | 0.77 | TSHR (0.43) | TSHRMEN1KMT2APTPN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106543081-B | Preparation method of 1-difluoroalkylisoquinoline | 四川理工学院 | 2020-02-18 | — | — | CN | claimed |
| CN-110536885-B | Process for producing difluoromethylene compound | 佐藤制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11084792-B2 | Method for producing difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3617197-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| CN-110536885-A | Method for producing difluoromethylene compound | SATO PHARMA | 2019-12-03 | — | — | CN | disclosed |
| CN-104761446-A | Preparation method of 2-bromo-2,2-difluoroacetyl chloride and 2-bromo-2,2-difluoro acetate and recycling method of waste difluoro trichloroethane | JIANGXI SUNWAY CHEM CO LTD | 2015-07-08 | — | — | CN | disclosed |
| CN-1095825-C | Process for preparing alkyl halodifluoroacetates | ATOCHEM ELF SA (FR) | 2002-12-11 | — | — | CN | disclosed |
| US-5780673-A | REACTING 1,1-DIFLUOROTETRAHALOETHANE WITH ALCOHOL IN PRESENCE OF OXYGEN AND FREE RADICAL INITIATOR | ELF ATOCHEM S.A. (FR) | 1998-07-14 | — | — | US | disclosed |
| CN-1169419-A | Process for preparation of alkyl halodifluoroacetates | ATOCHEM ELF SA (FR) | 1998-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | HACL2, MGLL, ABL1 | TSHR 439/4885MEN1 551/4885KMT2A 2108/4885 |
| US-11084792-B2 | Method for producing difluoromethylene compound | HACL2, MGLL, ABL1 | TSHR 439/4885MEN1 551/4885KMT2A 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.